Drug Search Results
More Filters [+]

AV-203

Alternative Names: av-203, av203, av 203
Latest Update: 2021-11-01
Latest Update Note: PubMed Publication

Product Description

AV-203 is a clinical-stage ErbB3 (HER3) inhibitory antibody candidate designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers, and AV-203 has demonstrated preclinical activity in a number of different tumor models including breast, head and neck, lung, ovarian and pancreatic cancers. (Sourced from: https://www.aveooncology.com/product-candidates/av-203/)

Mechanisms of Action: ERBB3 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AVEO
Company Location: BOSTON MA 02108
Company CEO: Michael Bailey
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AV-203

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

AV-203-12-101

P1

Completed

Oncology Solid Tumor Unspecified

2014-12-01

Recent News Events